"Insomnia has become a major public health problem in Western societies. In countries like Spain, for example, around 43% of the population experiences some symptoms of insomnia. According to data from a study by the Spanish Sleep Society (SES), the prevalence of chronic insomnia has tripled in the last two decades and now affects 14% of the Spanish adult population (around 5.4 million people)."
"According to the latest 2023 European Guidelines on Insomnia Treatment, cognitive-behavioral therapy for insomnia (CBT-I) is recommended as the first-line treatment for chronic insomnia in adults. Only if this therapy is ineffective or unavailable is the short-term use (no more than four weeks) of certain medications advised, such as benzodiazepines, benzodiazepine receptor agonists, and some antidepressants. In practice, however, many patients spend years taking these medications or suffering from insomnia symptoms that impair their quality of life without finding a treatment that improves their condition."
Insomnia prevalence is high in Western societies, with about 43% of people in Spain reporting some symptoms and chronic insomnia affecting 14% of adults (around 5.4 million). Chronic insomnia is defined as sleep difficulty that impairs daytime functioning at least three times per week for at least three months and is not explained by other factors. Clinical guidelines recommend cognitive-behavioral therapy for insomnia (CBT-I) as the first-line treatment; certain medications are advised only for short-term use when CBT-I is ineffective or unavailable. Many patients nonetheless use medications long-term or remain untreated. Insomnia is a complex, heterogeneous condition, prompting efforts to identify subtypes such as those with short sleep duration (less than six hours).
Read at english.elpais.com
Unable to calculate read time
Collection
[
|
...
]